• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Krystal Biotech (KRYS) Valuation Check After Recent Pullback And Mixed Earnings Multiple Signals

    Simply Wall St·03/27/2026 10:04:14
    Listen to the news

    Krystal Biotech: Stock Performance Context

    Krystal Biotech (KRYS) has drawn investor attention after a recent pullback, with the stock showing a 1-day return of a 1.39% decline, a 1-month return of a 5.81% decline, and a 1-year return of 37.57%.

    See our latest analysis for Krystal Biotech.

    Recent trading has been choppy, with a 30 day share price return of a 5.81% decline contrasting with a 1 year total shareholder return of 37.56%. This indicates that earlier momentum has cooled in the short term.

    If Krystal Biotech has you looking more broadly at healthcare opportunities, this could be a useful moment to scan other genetic medicine and biotech names through our 36 healthcare AI stocks

    With Krystal Biotech posting a 1 year total return of 37.56% and trading around a 63.63% intrinsic discount, the key question is whether the recent pullback offers a fresh entry point or whether the market already reflects future growth.

    Most Popular Narrative: 19.9% Undervalued

    Vestra’s fair value estimate of $314.00 sits well above Krystal Biotech’s last close at $251.40, and the gap is driven by a very specific growth story rather than broad sector optimism.

    The current narrative for Krystal is a story of global transition as it moves to repeat its U.S. success in overseas markets. Investors are laser-focused on the May 5, 2026, earnings update, where management is expected to provide more visibility on the "start-stop" dynamics of U.S. patient stabilization and the pace of German and French reimbursement negotiations.

    Read the complete narrative.

    Curious what underpins a fair value that sits well above today’s price? The narrative leans heavily on high margins, growing cash generation, and a multi year ramp that stretches far beyond a single product or geography.

    Result: Fair Value of $314.00 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, this hinges on timely European pricing decisions and Vyjuvek staying central to the story; any setback here could quickly challenge today’s optimistic narrative.

    Find out about the key risks to this Krystal Biotech narrative.

    Another View: Earnings Multiple Sends A Different Signal

    Vestra’s fair value of $314.00 is based on a 35x forward P/E. Today Krystal Biotech trades at about 35.9x, versus 21.1x for peers, 15.6x for the wider US Biotechs group, and a fair ratio of 25.5x. That rich gap could mean extra upside expectations or extra valuation risk for you to weigh.

    See what the numbers say about this price — find out in our valuation breakdown.

    NasdaqGS:KRYS P/E Ratio as at Mar 2026
    NasdaqGS:KRYS P/E Ratio as at Mar 2026

    Next Steps

    With sentiment clearly mixed, this is a good moment to check the numbers yourself and decide how you feel about the risk reward trade off. To see what investors are currently optimistic about, take a closer look at the 4 key rewards

    Ready to uncover more investment ideas?

    If Krystal Biotech has sharpened your interest, do not stop here; broaden your watchlist now so you do not miss other compelling setups.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.